These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23436927)

  • 1. Ki67 and proliferation in breast cancer.
    Pathmanathan N; Balleine RL
    J Clin Pathol; 2013 Jun; 66(6):512-6. PubMed ID: 23436927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma.
    Faratian D; Munro A; Twelves C; Bartlett JM
    Histopathology; 2009 Jan; 54(2):254-7. PubMed ID: 19207951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; van de Vijver MJ
    Eur J Surg Oncol; 1999 Aug; 25(4):356-63. PubMed ID: 10419704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Menstrual cycle could affect Ki67 expression in estrogen receptor-positive breast cancer patients.
    Horimoto Y; Arakawa A; Tanabe M; Kuroda K; Matsuoka J; Igari F; Himuro T; Yoshida Y; Tokuda E; Shimizu H; Hino O; Saito M
    J Clin Pathol; 2015 Oct; 68(10):825-9. PubMed ID: 26060263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between Ki67 and breast cancer prognosis.
    Kontzoglou K; Palla V; Karaolanis G; Karaiskos I; Alexiou I; Pateras I; Konstantoudakis K; Stamatakos M
    Oncology; 2013; 84(4):219-25. PubMed ID: 23364275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.
    Sabine VS; Sims AH; Macaskill EJ; Renshaw L; Thomas JS; Dixon JM; Bartlett JM
    Breast Cancer Res Treat; 2010 Jul; 122(2):419-28. PubMed ID: 20480226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.
    Penault-Llorca F; André F; Sagan C; Lacroix-Triki M; Denoux Y; Verriele V; Jacquemier J; Baranzelli MC; Bibeau F; Antoine M; Lagarde N; Martin AL; Asselain B; Roché H
    J Clin Oncol; 2009 Jun; 27(17):2809-15. PubMed ID: 19380452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer.
    Gudlaugsson E; Skaland I; Janssen EA; Smaaland R; Shao Z; Malpica A; Voorhorst F; Baak JP
    Histopathology; 2012 Dec; 61(6):1134-44. PubMed ID: 22963617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer.
    Williams DJ; Cohen C; Darrow M; Page AJ; Chastain B; Adams AL
    Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):431-6. PubMed ID: 21297447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.
    Batistatou A; Televantou D; Bobos M; Eleftheraki AG; Kouvaras E; Chrisafi S; Koukoulis GK; Malamou-Mitsi V; Fountzilas G
    Anticancer Res; 2013 May; 33(5):2139-45. PubMed ID: 23645767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values.
    Cserni G; Vörös A; Liepniece-Karele I; Bianchi S; Vezzosi V; Grabau D; Sapino A; Castellano I; Regitnig P; Foschini MP; Zolota V; Varga Z; Figueiredo P; Decker T; Focke C; Kulka J; Kaya H; Reiner-Concin A; Amendoeira I; Callagy G; Caffrey E; Wesseling J; Wells C
    Breast; 2014 Jun; 23(3):259-63. PubMed ID: 24613255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index.
    Jalava P; Kuopio T; Juntti-Patinen L; Kotkansalo T; Kronqvist P; Collan Y
    Histopathology; 2006 May; 48(6):674-82. PubMed ID: 16681683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptors and proliferation markers in primary and recurrent breast cancer.
    Jensen EV; Cheng G; Palmieri C; Saji S; Mäkelä S; Van Noorden S; Wahlström T; Warner M; Coombes RC; Gustafsson JA
    Proc Natl Acad Sci U S A; 2001 Dec; 98(26):15197-202. PubMed ID: 11734621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in oestrogen and progesterone receptors, HER-2, p53 expression and proliferation in ductal breast cancers in relation to histopathological grade.
    Zasławski R; Surowiak P; Paluchowski P; Dziegiel P; Maciejczyk A; Pudełko M; Wojnar A; Zabel M
    Folia Morphol (Warsz); 2005 Feb; 64(1):9-15. PubMed ID: 15832264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the Ki67 labeling index: a Japanese validation ring study.
    Niikura N; Sakatani T; Arima N; Ohi Y; Honma N; Kanomata N; Yoshida K; Kadoya T; Tamaki K; Kumaki N; Iwamoto T; Sugie T; Moriya T
    Breast Cancer; 2016 Jan; 23(1):92-100. PubMed ID: 24794952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
    Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
    Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonproliferative epithelial alteration and expression of estrogen receptor and Ki67 in the contralateral breast of women treated with tamoxifen for breast cancer.
    de Souza Sales JF; Cabello C; Alvarenga M; Torresan RZ; Duarte GM
    Breast; 2007 Apr; 16(2):197-203. PubMed ID: 17178225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic values of proliferative markers ki-67 and repp86 in breast cancer.
    Mohsenifar J; Almassi-Aghdam M; Mohammad-Taheri Z; Zare K; Jafari B; Atri M; Mortazavi SH; Azadeh P; Bagherzadeh M; Azargashb E; Rahimi F
    Arch Iran Med; 2007 Jan; 10(1):27-31. PubMed ID: 17198450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.